Physician

Haven Lindsay Caldwell-Sachar, D.O.

According to 2025 Medicare claims, Haven Caldwell-Sachar, D.O. (NPI: 1750677118) practices hematology/oncology in the Savannah, GA market, with the plurality of this provider's patient population coming from Chatham, GA. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 31404-6220.

Caldwell-Sachar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 763 traditional Medicare patients, billed 139,187 HCPCS/CPT codes, and received $2,808,461 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,295 prescription claims across 305 beneficiaries totaling $2,605,303 in drug costs, led by Revlimid (Lenalidomide). DME data shows 126 claims. Open Payments data shows 3 records totaling $54. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $14,037 to $2,808,461. Similarly, Part D prescription costs have risen steadily, from $8,765 to $2,605,303. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	77	150	$14,037
2018	214	1,729	$59,855
2019	143	2,284	$43,667
2020	139	18,207	$102,703
2021	325	42,008	$388,849
2022	540	80,762	$1,253,107
2023	622	109,645	$1,917,162
2024	763	139,187	$2,808,461

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	51	$8,765
2016	11	99	$140,742
2017	29	138	$149,445
2018	49	146	$104,254
2019	40	146	$103,259
2020	39	167	$466,670
2021	74	257	$205,306
2022	161	652	$1,154,284
2023	203	868	$2,166,527
2024	305	1,295	$2,605,303

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	24	$1,154
2022	N/R	28	$983
2023	N/R	48	$5,309
2024	N/R	126	$3,373

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	219	415	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	309	499	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	167	276	$12
36415	Insertion of needle into vein for collection of blood sample	500	1,127	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	511	1,309	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	58	1,442	$859,686
Imbruvica	Ibrutinib	18	504	$285,766
Pomalyst	Pomalidomide	11	308	$248,197
Jakafi	Ruxolitinib Phosphate	13	390	$194,551
Lenalidomide	Lenalidomide	12	252	$112,910

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	32	$1,558
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	11	$582
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	34	$539
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	28	$527
J8520	Capecitabine, oral, 150 mg	N	N/R	21	$166

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$54	Tempus AI, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Haven Lindsay Caldwell-Sachar, D.O.?

Tedicare shows public-source Medicare data for Haven Lindsay Caldwell-Sachar, D.O. (NPI 1750677118), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Haven Lindsay Caldwell-Sachar, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Haven Lindsay Caldwell-Sachar, D.O.?

Haven Lindsay Caldwell-Sachar, D.O. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Haven Lindsay Caldwell-Sachar, D.O. have Open Payments data?

Haven Lindsay Caldwell-Sachar, D.O. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.